BIOL RSI Chart
Last 7 days
-5.9%
Last 30 days
6.7%
Last 90 days
6.7%
Trailing 12 Months
-99%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 48.8M | 0 | 0 | 0 |
2023 | 48.8M | 50.8M | 49.7M | 49.2M |
2022 | 41.2M | 44.3M | 46.8M | 48.5M |
2021 | 26.1M | 32.3M | 35.3M | 39.2M |
2020 | 32.3M | 26.5M | 24.4M | 22.8M |
2019 | 46.5M | 43.0M | 40.7M | 37.8M |
2018 | 46.1M | 45.6M | 45.7M | 46.2M |
2017 | 51.7M | 50.5M | 48.1M | 46.9M |
2016 | 48.6M | 50.6M | 52.6M | 51.8M |
2015 | 47.0M | 48.7M | 47.2M | 48.5M |
2014 | 53.4M | 49.3M | 49.7M | 47.7M |
2013 | 59.6M | 61.7M | 60.3M | 56.4M |
2012 | 50.6M | 51.1M | 51.8M | 57.4M |
2011 | 30.7M | 36.5M | 43.4M | 48.9M |
2010 | 0 | 37.1M | 30.8M | 24.6M |
2009 | 0 | 0 | 0 | 43.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 07, 2022 | lord jonathan t md | sold | -2,652 | 0.75 | -3,537 | - |
Apr 28, 2022 | roper jess | back to issuer | - | - | -345 | - |
Apr 28, 2022 | beaver john r | back to issuer | - | - | -554 | president & ceo |
Apr 28, 2022 | lord jonathan t md | back to issuer | - | - | -1,395 | - |
Dec 15, 2021 | lord jonathan t md | sold | -4,194 | 0.38 | -11,038 | - |
Nov 30, 2021 | beaver john r | bought | 31,500 | 0.45 | 70,000 | president & ceo |
Aug 20, 2021 | beaver john r | bought | 21,350 | 0.61 | 35,000 | president & ceo |
May 19, 2021 | beaver john r | bought | 30,000 | 0.75 | 40,000 | president & ceo |
Dec 18, 2020 | schuler education foundation | sold | -52,576 | 0.28 | -187,774 | - |
Dec 17, 2020 | schuler education foundation | sold | -160,348 | 0.28 | -572,671 | - |
Which funds bought or sold BIOL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 1,919 | 1,919 | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -16.00 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -26.00 | - | -% |
May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 14.00 | 14.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -91.83 | -2,707 | 38.00 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | new | - | 22,143 | 22,143 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -12,035 | - | -% |
May 15, 2024 | Royal Bank of Canada | new | - | 9,000 | 9,000 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 188 | -7,916 | 7,560 | -% |
May 14, 2024 | Qube Research & Technologies Ltd | new | - | 759 | 759 | -% |
Unveiling Biolase Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Biolase Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Biolase Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -24.9% | 10,131,000 | 13,490,000 | 10,921,000 | 14,286,000 | 10,467,000 | 14,051,000 | 12,010,000 | 12,235,000 | 10,166,000 | 12,407,500 | 9,531,000 | 9,134,000 | 8,116,000 | 8,520,000 | 6,539,000 | 2,938,000 | 4,783,000 | 10,182,000 | 8,646,000 | 8,645,000 | 10,326,000 |
Cost Of Revenue | -31.8% | 6,795,000 | 9,966,500 | 7,175,000 | 8,168,000 | 7,130,000 | 10,455,000 | 9,565,000 | 7,094,000 | 5,437,000 | 7,502,000 | 4,689,000 | 5,093,000 | 5,375,000 | 6,915,000 | 4,265,000 | 1,997,000 | 3,430,000 | 5,765,000 | 5,677,000 | 5,265,000 | 6,804,000 |
Gross Profit | -5.3% | 3,336,000 | 3,523,500 | 3,746,000 | 6,118,000 | 3,337,000 | 3,596,000 | 2,445,000 | 5,141,000 | 4,729,000 | 4,905,500 | 4,842,000 | 4,041,000 | 2,741,000 | 1,605,000 | 2,274,000 | 941,000 | 1,353,000 | 4,417,000 | 2,969,000 | 3,380,000 | 3,522,000 |
Operating Expenses | -8.6% | 7,862,000 | 8,600,000 | 7,443,000 | 9,990,000 | 8,628,000 | 12,022,500 | 10,096,000 | 10,196,000 | 8,935,000 | 9,335,000 | 7,499,000 | 7,324,000 | 8,803,000 | 7,143,500 | 5,941,000 | 4,920,000 | 6,705,000 | 7,460,000 | 7,851,000 | 6,717,000 | 7,886,000 |
S&GA Expenses | -20.0% | 3,383,000 | 4,227,500 | 3,402,000 | 6,189,000 | 4,622,000 | 6,451,000 | 5,008,000 | 5,402,000 | 4,814,000 | 5,024,000 | 3,451,000 | 3,311,000 | 3,553,000 | 3,767,000 | 2,678,000 | 2,093,000 | 2,704,000 | 3,730,500 | 3,515,000 | 3,272,000 | 3,879,000 |
R&D Expenses | -22.3% | 1,283,000 | 1,651,500 | 1,362,000 | 1,444,000 | 1,547,000 | 2,088,500 | 1,979,000 | 1,653,000 | 1,544,000 | 1,542,500 | 1,540,000 | 1,162,000 | 1,803,000 | 1,051,000 | 963,000 | 690,000 | 991,000 | 1,095,500 | 1,126,000 | 1,124,000 | 1,424,000 |
EBITDA Margin | -1.2% | -0.33 | -0.32 | -0.42 | -0.50 | -0.56 | -0.55 | -0.47 | -0.38 | -0.29 | -0.36 | -0.42 | -0.35 | -0.58 | - | - | - | - | - | - | - | - |
Interest Expenses | -1.0% | 494,000 | 499,000 | 489,000 | 460,000 | 470,000 | 409,000 | 367,000 | 366,000 | 377,000 | 443,000 | 442,000 | 438,000 | 448,000 | 443,000 | 972,000 | -19,000 | 485,000 | 469,000 | 484,000 | 401,000 | 430,000 |
Income Taxes | 222.6% | 19,000 | -15,500 | 15,000 | 31,000 | 1,000 | 86,000 | -17,000 | 23,000 | 17,000 | 71,500 | 14,000 | -80,000 | 60,000 | 143,000 | -15,000 | 53,000 | -19,000 | -112,500 | 26,000 | 28,000 | 15,000 |
Earnings Before Taxes | -21.1% | -6,466,000 | -5,341,500 | -4,574,000 | -4,837,000 | -5,848,000 | -9,774,500 | -8,404,000 | -5,588,000 | -4,759,000 | -5,207,500 | -3,262,000 | -782,000 | -6,841,000 | -6,061,000 | 27,000 | -4,644,000 | -6,025,000 | -3,695,000 | -5,452,000 | -3,871,000 | -4,885,000 |
EBT Margin | -3.7% | -0.43 | -0.42 | -0.50 | -0.57 | -0.61 | -0.59 | -0.51 | -0.42 | -0.34 | -0.41 | -0.48 | -0.42 | -0.67 | - | - | - | - | - | - | - | - |
Net Income | -21.8% | -6,485,000 | -5,326,000 | -4,589,000 | -4,868,000 | -5,849,000 | -9,860,500 | -8,387,000 | -5,611,000 | -4,776,000 | -5,279,000 | -3,276,000 | -702,000 | -6,901,000 | -6,140,000 | 12,000 | -4,697,000 | -6,006,000 | -3,582,500 | -5,478,000 | -3,899,000 | -4,900,000 |
Net Income Margin | -3.8% | -0.44 | -0.42 | -0.51 | -0.57 | -0.61 | -0.59 | -0.51 | -0.43 | -0.34 | -0.41 | -0.48 | -0.42 | -0.68 | - | - | - | - | - | - | - | - |
Free Cashflow | -140.6% | -5,938,000 | -2,468,000 | -2,770,000 | -3,919,000 | -6,245,000 | -6,053,000 | -9,224,000 | -6,886,000 | -8,325,000 | -3,415,000 | -3,683,000 | -3,812,000 | -6,507,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.1% | 34.00 | 35.00 | 39.00 | 40.00 | 42.00 | 38.00 | 43.00 | 51.00 | 50.00 | 55.00 | 59.00 | 61.00 | 63.00 | 41.00 | 42.00 | 28.00 | 25.00 | 32.00 | 28.00 | 32.00 | 34.00 |
Current Assets | 0.6% | 25.00 | 25.00 | 28.00 | 28.00 | 32.00 | 29.00 | 34.00 | 44.00 | 44.00 | 49.00 | 53.00 | 55.00 | 58.00 | 35.00 | 36.00 | 23.00 | 20.00 | 27.00 | 23.00 | 27.00 | 29.00 |
Cash Equivalents | -3.1% | 6.00 | 7.00 | 8.00 | 7.00 | 7.00 | 4.00 | 10.00 | 20.00 | 22.00 | 30.00 | 34.00 | 37.00 | 41.00 | 18.00 | 19.00 | 6.00 | 2.00 | 6.00 | 2.00 | 4.00 | 3.00 |
Inventory | -1.4% | 11.00 | 11.00 | 14.00 | 13.00 | 18.00 | 16.00 | 16.00 | 17.00 | 15.00 | 13.00 | 14.00 | 13.00 | 12.00 | 11.00 | 13.00 | 12.00 | 12.00 | 11.00 | 12.00 | 12.00 | 12.00 |
Net PPE | -12.3% | 5.00 | 6.00 | 6.00 | 6.00 | 5.00 | 4.00 | 4.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 |
Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Liabilities | 2.8% | 34.00 | 33.00 | 33.00 | 32.00 | 34.00 | 33.00 | 29.00 | 29.00 | 30.00 | 30.00 | 28.00 | 28.00 | 30.00 | 31.00 | 28.00 | 26.00 | 25.00 | 28.00 | 29.00 | 29.00 | 27.00 |
Current Liabilities | 9.0% | 21.00 | 20.00 | 20.00 | 18.00 | 19.00 | 18.00 | 14.00 | 14.00 | 13.00 | 14.00 | 13.00 | 13.00 | 11.00 | 11.00 | 21.00 | 21.00 | 24.00 | 26.00 | 14.00 | 13.00 | 15.00 |
Long Term Debt | -4.9% | 11.00 | 12.00 | - | - | - | 13.00 | - | - | - | - | - | - | - | 16.00 | - | - | - | - | 13.00 | 13.00 | 11.00 |
LT Debt, Current | 23.6% | 3.00 | 2.00 | - | - | - | 1.00 | - | - | - | - | - | - | - | - | 13.00 | 14.00 | 14.00 | 13.00 | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.00 | - | - | - | - | 13.00 | 13.00 | 11.00 |
Shareholder's Equity | -683.0% | -1.93 | -0.25 | 0.00 | 7.00 | 8.00 | 5.00 | 14.00 | 22.00 | 21.00 | 25.00 | 30.00 | 33.00 | 34.00 | 10.00 | 14.00 | 1.00 | 0.00 | 0.00 | - | 4.00 | 7.00 |
Retained Earnings | -2.0% | -323 | -316 | -311 | -306 | -302 | -296 | -286 | -277 | -272 | -267 | -262 | -258 | -258 | -251 | -245 | -245 | -240 | -234 | -230 | -225 | -221 |
Additional Paid-In Capital | 1.5% | 322 | 317 | 313 | 314 | 311 | 302 | 0.00 | 0.00 | 0.00 | 293 | 293 | 293 | 292 | 262 | 259 | 247 | 236 | 236 | 231 | 230 | 229 |
Shares Outstanding | 873.6% | 33.00 | 3.00 | 2.00 | 1.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 7.00 | - | - | - | - | - | - | - | 104 | - | - | - | 104 | - | - | - | 12.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -160.1% | -5,938 | -2,283 | -2,588 | -3,562 | -5,658 | -5,582 | -6,546 | -6,612 | -8,021 | -3,104 | -3,598 | -3,509 | -6,499 | -1,348 | -2,108 | -5,205 | -4,134 | -4,672 | -1,447 | -1,593 | -5,034 |
Share Based Compensation | -37.9% | 113 | 182 | 275 | 84.00 | 691 | 612 | 591 | 891 | 209 | 174 | 191 | 369 | 928 | 1,003 | 848 | 800 | 719 | 768 | 770 | 447 | 757 |
Cashflow From Investing | 6666.7% | 197 | -3.00 | -182 | -357 | -587 | -471 | -2,678 | -274 | -304 | -311 | -85.00 | -303 | -8.00 | -18.00 | 3.00 | -72.00 | -9.00 | -69.00 | -13.00 | -117 | -8.00 |
Cashflow From Financing | 538.1% | 5,647 | 885 | 3,756 | 4,276 | 8,517 | -32.00 | -214 | 4,849 | - | 68.00 | 75.00 | -14.00 | 29,825 | -53.00 | 15,391 | 9,128 | -117 | 8,305 | -50.00 | 2,463 | 3.00 |
Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net revenue | $ 10,131 | $ 10,467 |
Cost of revenue | 6,795 | 7,130 |
Gross profit | 3,336 | 3,337 |
Operating expenses: | ||
Sales and marketing | 3,383 | 4,622 |
General and administrative | 3,196 | 2,459 |
Engineering and development | 1,283 | 1,547 |
Total operating expenses | 7,862 | 8,628 |
Loss from operations | (4,526) | (5,291) |
Gain (loss) on foreign currency transactions | (96) | 20 |
Interest expense, net | (622) | (577) |
Other income (loss), net | (1,222) | 0 |
Non-operating loss, net | (1,940) | (557) |
Loss before income tax provision | (6,466) | (5,848) |
Income tax provision | (19) | (1) |
Net loss | (6,485) | (5,849) |
Other comprehensive loss items: | ||
Foreign currency translation adjustments | (86) | 80 |
Comprehensive loss | (6,571) | (5,769) |
Net loss | (6,485) | (5,849) |
Deemed dividend on convertible preferred stock | 0 | 0 |
Net loss attributable to common stockholders | $ (6,485) | $ (5,849) |
Net loss per share attributable to common stockholders: | ||
Earnings Per Share, Basic | $ (0.36) | $ (17.83) |
Earnings Per Share, Diluted | $ (0.36) | $ (17.83) |
Shares used in the calculation of net loss per share: | ||
Weighted Average Number of Shares Outstanding, Basic | 17,842 | 328 |
Weighted Average Number of Shares Outstanding, Diluted | 17,842 | 328 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,393 | $ 6,566 |
Accounts receivable, less allowance of $216 and $244 as of March 31, 2024 and December 31, 2023, respectively | 5,687 | 5,483 |
Inventory | 11,273 | 11,433 |
Prepaid expenses and other current assets | 1,652 | 1,381 |
Total current assets | 25,005 | 24,863 |
Property, plant, and equipment, net | 4,846 | 5,525 |
Goodwill | 2,926 | 2,926 |
Right-of-use assets, leases | 1,313 | 1,519 |
Other assets | 263 | 268 |
Total assets | 34,353 | 35,101 |
Current liabilities: | ||
Accounts payable | 4,915 | 6,065 |
Accrued liabilities | 7,589 | 7,518 |
Stock warrant liability | 3,780 | 1,363 |
Deferred revenue, current portion | 2,343 | 2,452 |
Current portion of term loans | 2,800 | 2,265 |
Total current liabilities | 21,427 | 19,663 |
Deferred revenue | 223 | 256 |
Warranty accrual | 598 | 593 |
Non current term loans, net of discount | 11,207 | 11,782 |
Non current operating lease liability | 542 | 772 |
Other liabilities | 87 | 79 |
Total liabilities | 34,084 | 33,145 |
Mezzanine Equity: | ||
Total mezzanine equity | 2,203 | 2,203 |
Stockholders' equity: | ||
Common stock, par value $0.001 per share; 180,000 shares authorized, 33,257 and 3,416 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 33 | 3 |
Additional paid-in-capital | 321,957 | 317,103 |
Accumulated other comprehensive loss | (639) | (553) |
Accumulated deficit | (323,285) | (316,800) |
Total stockholders' equity (deficit) | (1,934) | (247) |
Total liabilities, convertible redeemable preferred stock and stockholders' equity (deficit) | 34,353 | 35,101 |
Series H Preferred Stock [Member] | ||
Mezzanine Equity: | ||
Preferred stock Value | 346 | 346 |
Series J Convertible Preferred Stock [Member] | ||
Mezzanine Equity: | ||
Preferred stock Value | $ 1,857 | $ 1,857 |